Medmira Inc (TSE:MIR) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Medmira Inc. reports a significant corporate milestone with the US FDA 510(k) clearance for its Reveal G4 Rapid HIV-1/2 antibody test, set to bolster its U.S. market share and revenues. The company also completed supporting studies for Health Canada and expanded its Commercialisation Department, aiming to strengthen its North American presence. Despite these advancements, Medmira experienced a net loss of $590,789 this quarter, with a slight increase in working capital deficit.
For further insights into TSE:MIR stock, check out TipRanks’ Stock Analysis page.